ArticleMolecular omics2019
Exploratory metabolomic study to identify blood-based biomarkers as a potential screen for colorectal cancer.
Article in Molecular omics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plasma metabolites, metabolic risk score and colorectal cancer risk: a prospective cohort study.European journal of epidemiology · 2025Article
- Gut microbiome modulation by Weifuchun Capsules alleviates chronic atrophic gastritis: a combined microbiota and metabolomics approach.Frontiers in microbiology · 2025Article
- Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer.Frontiers in oncology · 2021Article
- Metabonomic Variation of Exopolysaccharide fromOncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductioncolorectal cancer (CRC) continues to be difficult to diagnose due to the lack of reliable and predictive biomarkers.
objectiveto identify blood-based biomarkers that can be used to distinguish CRC cases from controls.
methodsa workflow for untargeted followed by targeted metabolic profiling was conducted on the plasma samples of 26 CRC cases and ten healthy volunteers (controls) using liquid chromatography-mass spectrometry (LCMS). The data acquired in the untargeted scan was processed and analyzed using MarkerView™ software. The significantly different ions that distinguish CRC cases from the controls were identified using a mass-based human metabolome search. The result was further used to inform the targeted scan workflow.
resultsthe untargeted scan yielded putative biomarkers some of which were related to the folate-dependent one-carbon metabolism (FOCM). Analysis of the targeted scan found the plasma levels of nine FOCM metabolites to be significantly different between cases and controls. The classification models of the cases and controls, in both the targeted and untargeted approaches, each yielded a 97.2% success rate after cross-validation.
conclusionwe have identified plasma metabolites with screening potential to discriminate between CRC cases and controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.